Drug Search Results
More Filters [+]

MEB-1170

Alternative Names: MEB-1170, MEB1170, MEB 1170
Latest Update: 2023-02-28
Latest Update Note: Clinical Trial Update

Product Description

MEB-1170, was approved by the FDA on October 6th, 2022 to enter Phase 1 human clinical trials (see News tab). MEB-1170 is an oral analgesic to replace Oxycodone. It is designed and developed to treat pain without respiratorty depression which is the cause of death in overdoses. MEB-1170 shows no abuse potential in pre-clinical studies. MEB-1170 holds the promise to solve the opioid crisis. (Sourced from: https://mebiasdiscovery.com/pipeline/)

Mechanisms of Action: OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mebias Discover
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MEB-1170

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Pain Unspecified|Healthy Volunteers

Phase 0: Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MEB-1170-101

P1

Unknown status

Healthy Volunteers|Pain Unspecified

2023-10-01

Recent News Events